health
March 15, 2026
FDA Chaos Threatens Trump Administration Drug Agenda
The Trump administration recently celebrated one year of embracing the movement to Make America Healthy Again. Unfortunately, many of these successes are overshadowed by slapdash decision-making at a key health agency, which significantly undermines the administration’s goals, threatens treatment access, choice, and safety for American patients, and hinders our longstanding reputation as a world leader in medical innovation.
TL;DR
- The FDA has experienced significant workforce reductions and high leadership turnover in 2025, including multiple leaders for the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
- The agency's guidance has become shortsighted, hypocritical, and self-contradictory, deviating from its core mission of following science.
- Moderna faced confusing and contradictory messaging from the FDA regarding its mRNA flu vaccine approval process.
- Other manufacturers have faced abrupt rejections of new treatments, sometimes reversing the FDA's prior positions.
- The FDA has inconsistently altered its requirements for drug approval, loosening standards for biosimilars and allowing single pivotal trials for some drugs, while increasing evidence requirements for others.
- This regulatory unpredictability discourages investment in new treatments and undermines America's leadership in medical innovation.
- The chaos at the FDA ultimately impacts American patients by delaying treatments and eroding confidence in approved medicines.
- Presidential intervention, while sometimes prompting course correction, is not a substitute for consistent and predictable FDA standards.
Continue reading the original article